TMO Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.
Company profile
Ticker
TMO
Exchange
Website
CEO
Marc N. Casper
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
Thermo Electron Corp
SEC CIK
Corporate docs
IRS number
42209186
TMO stock data
()
Investment data
Securities sold
Number of investors
Calendar
1 May 20
11 Jul 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | 6.23B | 6.83B | 6.27B | 6.32B | |
| Net income | 788M | 1B | 760M | 1.12B | |
| Diluted EPS | 1.97 | 2.49 | 1.88 | 2.77 | |
| Net profit margin | 12.65% | 14.67% | 12.12% | 17.72% | |
| Operating income | 906M | 1.23B | 946M | 1.5B | |
| Net change in cash | 582M | 1.13B | -1.02B | 1.18B | |
| Cash on hand | 2.98B | 2.4B | 1.27B | 2.29B | |
| Cost of revenue |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 25.54B | 24.36B | 20.92B | 18.27B | |
| Net income | 3.7B | 2.94B | 2.23B | 2.02B | |
| Diluted EPS | 9.17 | 7.24 | 5.59 | 5.09 | |
| Net profit margin | 14.47% | 12.06% | 10.64% | 11.06% | |
| Operating income | 4.59B | 3.78B | 2.96B | 2.46B | |
| Net change in cash | 296M | 768M | 549M | 333.9M | |
| Cash on hand | 2.4B | 2.1B | 1.34B | 786M | |
| Cost of revenue | 2.5B | 1.69B |
Financial data from company earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 2 Jul 20 | Boxer Michael A | Common Stock | Payment of exercise | Dispose F | No | 365.89 | 176 | 64.4K | 9,471 |
| 27 Jun 20 | Sperling Scott M | Phantom Stock Units Common Stock | Grant | Aquire A | No | 0 | 66.78 | 0 | 15,850.93 |
| 2 Jun 20 | Casper Marc N | Common Stock | Gift | Aquire G | No | 0 | 34,500 | 0 | 34,500 |
| 2 Jun 20 | Casper Marc N | Common Stock | Gift | Dispose G | No | 0 | 34,500 | 0 | 240,445.53 |
| 2 Jun 20 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | 350.08 | 817 | 286.02K | 274,945.53 |
| 2 Jun 20 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | 349.52 | 13,978 | 4.89M | 275,762.53 |
| 2 Jun 20 | Casper Marc N | Common Stock | Option exercise | Aquire M | No | 124.28 | 14,795 | 1.84M | 289,740.53 |
| 2 Jun 20 | Casper Marc N | Stock Option Common Stock | Option exercise | Dispose M | No | 124.28 | 14,795 | 1.84M | 0 |
| 1 Jun 20 | Stephen Williamson | Common Stock | Sell | Dispose S | Yes | 348 | 2,500 | 870K | 37,989 |
| 1 Jun 20 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | 350.37 | 7,587 | 2.66M | 274,945.53 |
Institutional ownership Q1 2020
87.4% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1626 |
| Opened positions | 129 |
| Closed positions | 146 |
| Increased positions | 600 |
| Reduced positions | 705 |
13F shares |
Current |
|---|---|
| Total value | 1.25T |
| Total shares | 345.32M |
| Total puts | 1.23M |
| Total calls | 1.11M |
| Total put/call ratio | 1.1 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 32.13M | $9.11B |
| BLK BlackRock | 27.03M | $7.66B |
| Capital World Investors | 16.82M | $4.77B |
| STT State Street | 16.5M | $4.68B |
| N Price T Rowe Associates | 16.48M | $4.67B |
| Massachusetts Financial Services | 15.47M | $4.39B |
| Capital Research Global Investors | 11.79M | $3.34B |
| FMR | 11.24M | $3.19B |
| MS Morgan Stanley | 7.56M | $2.14B |
| Wellington Management | 7.53M | $2.14B |
Financial report summary
?Competition
Bio-Rad Laboratories • Quidel • Dionex • Mesa Laboratories • Accelerate Diagnostics • Waters • Molecular Devices • Caliper Life Sciences • Luminex • CepheidManagement Discussion
- Sales in the first quarter of 2020 were $6.23 billion, an increase of $105 million from the first quarter of 2019. Sales increased $35 million due to acquisitions, net of a divestiture. The unfavorable effects of currency translation resulted in a decrease in revenues of $65 million in 2020. Aside from the effects of acquisitions/divestitures and currency translation, revenues increased $135 million (2%) primarily due to increased demand in the quarter compared to the 2019 quarter. Sales were particularly strong to customers in diagnostic and healthcare markets, driven in part by demand for products supporting those diagnosing and treating the COVID-19 virus, as well as to customers in pharma and biotech end markets. Sales to academic and government customers decreased due primarily to closure of academic labs, initially in China and then globally as the quarter progressed. Sales to customers in industrial markets decreased primarily due to lower demand in China from business slowing and closures related to COVID-19 as well as strong comparative sales in the first quarter of 2019. The first quarter of 2020 had one less selling day than the first quarter of 2019 which reduced revenues by nearly 1%. Sales growth was particularly strong in Europe and, to a lesser extent, North America while sales decreased in the Asia-Pacific region.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
achieve, addressing, adhere, aged, amended, analyze, assessing, assumption, attention, attractive, bankruptcy, begun, behavior, bribery, bridge, catastrophic, CBM, clarify, conflict, consuming, Corrupt, corruption, cyclical, cyclicality, deal, delinquency, diagnose, diagnosing, disposal, divert, doubtful, driven, duration, encounter, entity, excellent, external, Extraordinary, false, formally, forward, fraud, genetic, hamper, home, improper, input, instability, institute, instituted, investigatory, lapse, laundering, led, mobilized, molecular, motion, negotiate, nonmonetary, ordinary, pandemic, partly, persist, point, precautionary, progressed, prohibit, prolonged, proven, purpose, QIAGEN, ramping, receipt, recession, recovered, reliance, reserve, returning, review, science, shareholder, similarly, simplify, slowdown, spread, strain, Supplemental, supplier, tender, transplant, travel, treating, treatment, unanticipated, unconditional, undetermined, unpredictable, utilize, volatility, withdrew, workplace, worsen, wrongful
Removed:
abroad, Advanced, Affordable, approach, approximate, Asia, Becton, Bioprocessing, called, care, carried, charging, classification, commenced, commencement, comprised, consistent, corroborated, culture, determinable, Dickinson, diluted, direct, discontinued, embedded, encouraging, established, exclude, exemption, exercise, expired, exportation, extend, favor, February, Gatan, grew, guarantee, holding, holiday, identical, immunodiagnostic, implicit, importation, imposing, inception, incremental, initial, intention, land, leased, leaving, lessee, lessor, marketable, membership, mutual, noncancelable, noted, October, office, percentage, pioneer, promoting, publicly, referendum, rental, request, residual, restated, retirement, ROU, satisfy, Singapore, single, social, stemming, sublease, taxing, technique, terminate, threatened, traded, unit, unobservable, valuation, voted, yield
Financial reports
10-Q
2020 Q1
Quarterly report
1 May 20
10-K
2019 FY
Annual report
26 Feb 20
10-Q
2019 Q3
Quarterly report
1 Nov 19
10-Q
2019 Q2
Quarterly report
2 Aug 19
10-Q
2019 Q1
Quarterly report
3 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
2 Nov 18
10-Q
2018 Q2
Quarterly report
3 Aug 18
10-Q
2018 Q1
Quarterly report
4 May 18
10-K
2017 FY
Annual report
28 Feb 18
Current reports
8-K
Thermo Fisher Scientific Provides Update to Second Quarter Outlook
6 Jul 20
8-K
Entry into a Material Definitive Agreement
11 Jun 20
8-K
Submission of Matters to a Vote of Security Holders
22 May 20
8-K
Regulation FD Disclosure
13 May 20
8-K
Entry into a Material Definitive Agreement
23 Apr 20
8-K
Thermo Fisher Scientific Reports First Quarter 2020 Results
22 Apr 20
8-K
Thermo Fisher Scientific Provides COVID-19 Business Update
6 Apr 20
8-K
Entry into a Material Definitive Agreement
2 Apr 20
8-K
Entry into a Material Definitive Agreement
26 Mar 20
8-K
Other Events
23 Mar 20
Registration and prospectus
SC TO-T/A
Third party tender offer statement (amended)
6 Jul 20
SC TO-T/A
Third party tender offer statement (amended)
1 Jul 20
SC TO-T/A
Third party tender offer statement (amended)
29 Jun 20
SC TO-T/A
Third party tender offer statement (amended)
22 Jun 20
SC TO-T/A
Third party tender offer statement (amended)
15 Jun 20
SC TO-T/A
Third party tender offer statement (amended)
8 Jun 20
SC TO-T/A
Third party tender offer statement (amended)
2 Jun 20
SC TO-T/A
Third party tender offer statement (amended)
26 May 20
SC TO-T/A
Third party tender offer statement (amended)
18 May 20
SC TO-T/A
Third party tender offer statement (amended)
11 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
7 Apr 20
DEF 14A
Definitive proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
9 Apr 19
DEF 14A
Definitive proxy
9 Apr 19
DEF 14A
Definitive proxy
10 Apr 18
DEFA14A
Additional proxy soliciting materials
10 Apr 18
DEFA14A
Additional proxy soliciting materials
16 May 17
DEF 14A
Definitive proxy
4 Apr 17
DEFA14A
Additional proxy soliciting materials
4 Apr 17
DEF 14A
Definitive proxy
5 Apr 16
Other
SD
Conflict minerals disclosure
29 May 20
SD
Conflict minerals disclosure
31 May 19
SD
Conflict minerals disclosure
30 May 18
CERTNYS
Certification of approval for NYSE listing
24 Jul 17
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
16 Mar 17
CERTNYS
Certification of approval for NYSE listing
12 Sep 16
CERTNYS
Certification of approval for NYSE listing
9 Aug 16
SD
Conflict minerals disclosure
31 May 16
UPLOAD
Letter from SEC
10 May 16
Ownership
4
THERMO FISHER SCIENTIFIC / Michael A Boxer ownership change
6 Jul 20
4
THERMO FISHER SCIENTIFIC / SCOTT M SPERLING ownership change
30 Jun 20
4
THERMO FISHER SCIENTIFIC / MARC N CASPER ownership change
4 Jun 20
4
THERMO FISHER SCIENTIFIC / Stephen Williamson ownership change
2 Jun 20
4
THERMO FISHER SCIENTIFIC / MARC N CASPER ownership change
2 Jun 20
4
THERMO FISHER SCIENTIFIC / JUDY C LEWENT ownership change
21 May 20
4
THERMO FISHER SCIENTIFIC / SCOTT M SPERLING ownership change
21 May 20
4
THERMO FISHER SCIENTIFIC / DION J WEISLER ownership change
21 May 20
4
THERMO FISHER SCIENTIFIC / Debora L Spar ownership change
21 May 20
4
THERMO FISHER SCIENTIFIC / LARS REBIEN SORENSEN ownership change
21 May 20
Patents
GRANT
Utility
Sample preparation apparatus and method for elemental analysis spectrometer
7 Jul 20
A sample preparation apparatus for an elemental analysis system comprising a sample combustion and/or reduction and/or pyrolysis arrangement for receiving a sample of material to be analysed, and producing therefrom a sample gas flow containing atoms, molecules and/or compounds; a gas chromatography (GC) column into which the sample gas flow is directed; a heater for heating at least a part of the GC column; and a controller for controlling the heater.
GRANT
Utility
Methods and apparatus for semiconductor sample workflow
7 Jul 20
Apparatus and methods are described for the automated transfer and storage of transmission electron microscope (TEM) and scanning/transmission electron microscope (STEM) lamella samples throughout a semiconductor manufacturing facility using existing automation infrastructure such as a Front Opening Unified Pod (FOUP).
APP
Utility
Method for Identification of the Monoisotopic Mass of Species of Molecules
2 Jul 20
A method for identification of the monoisotopic mass or a parameter correlated to the mass of the isotopes of the isotope distribution of at least one species of molecules contained in a sample and/or originated from a sample by at least an ionization process includes measuring a mass spectrum of the sample with a mass spectrometer, dividing at least one range of measured m/z values of the mass spectrum into fractions, assigning at least some of the fractions to one processor of several provided processors, deducing for each of the at least one species of molecules an isotope distribution of their ions having a specific charge z, deducing from at least one deduced isotope distribution the monoisotopic mass or a parameter correlated to the mass of the isotopes of the isotope distribution of the species of molecules.
APP
Utility
Image Analysis System and Method
2 Jul 20
An image analysis system includes a video camera that collects YUV color images of a liquid sample disposed between a capital and a pedestal, the color images being collected while a light source shines light through an optical beam path between the capital and the pedestal, and a processor adapted to i) obtain from the YUV color images a grayscale component image and a light scatter component image, and ii) obtain at least one binary image of the grayscale component image and at least one binary image of the light scatter component image.
GRANT
Utility
Cyanine compounds
30 Jun 20
Compounds used as labels with properties comparable to known fluorescent compounds.